Features | Partner Sites | Information | LinkXpress
Sign In
ElsMed
Ampronix
Schiller

Gold Nanoparticles to Deliver Powerful Radioactive Particles Directly to Tumors for Treatment

By Medimaging International staff writers
Posted on 18 Feb 2013
Researchers have demonstrated the ability to harness powerful radioactive particles and target them toward small cancerous tumors while doing negligible damage to healthy organs and tissues.

The study’s findings were published in February 2012 in the journal PLOS ONE. Typically, when radiation treatment is recommended for cancer patients, doctors are able to choose from several radiopharmaceuticals that use low-energy radiation particles, known as beta particles. For quite a while, scientists have been examining how to use alpha particles, which are radioactive particles that contain a large amount of energy, in cancer treatments. The challenges to using alpha particles, which are more than 7,000 times heavier than beta particles, include confining the powerful alpha particles in a selected location inside the body while preventing radiation from wandering to healthy organs and tissues.

“If you think of beta particles as slingshots or arrows, alpha particles would be similar to cannon balls,” said J. David Robertson, director of research at the University of Missouri (MU; Columbia, USA) research reactor and professor of chemistry in the College of Arts and Science. “Scientists have had some successes using alpha particles recently, but nothing that can battle different cancers. For example, a current study using radium-223 chloride, which emits alpha particles, has been fast-tracked by the US Food and Drug Administration because it has been shown to be effective in treating bone cancer. However, it only works for bone cancer because the element, radium, is attracted to the bone and stays there. We believe we have found a solution that will allow us to target alpha particles to other cancer sites in the body in an effective manner.”

Dr. Robertson and researchers from Oak Ridge National Laboratory (Oak Ridge, TN, USA) and the School of Medicine at the University of Tennessee (Knoxville, USA) used the element actinium, which is an element known as an alpha emitter because it generates alpha particles. As it decays, actinium creates three additional elements that produce alpha particles. Because of the strength of these particles, keeping the elements positioned at cancer sites was not possible, until the investigators designed a gold-plated nanoparticle that serves as a holding cell for the elements, keeping them in place at the cancer site.

Dr. Robertson’s nanoparticle is a layered device. At the core is the original element, actinium. The researchers then added four layers of material and then coated the nanoparticle with gold. This made the nanoparticle strong enough to hold the actinium—and the other alpha emitters that are ultimately created—long enough for any alpha particles to destroy nearby cancer cells. “Holding these alpha emitters in place is a technical challenge that researchers have been trying to overcome for 15 years,” Dr. Robertson said. “With our nanoparticle design, we are able to keep more than 80% of the element inside the nanoparticle 24 hours after it is created.”

Whereas alpha particles are very powerful, they do not travel very far, so when the nanoparticles get close to cancer cells, the alpha particles move out and destroy the cell more successfully than current radiation therapy options, according to Dr. Robertson. “Previously, basic research had established that scientists can attach antibodies onto gold nanoparticles that help drive the nanoparticles to the tumor sites in the body,” Dr. Robertson said. “Without that groundbreaking work, we would not have been able to put this puzzle together.”

The preliminary results of this research are promising. If additional studies are successful within the next few years, MU officials will request authority from the federal government to begin human drug development (referred to as the investigative new drug [IND] status). After this status has been granted, researchers may conduct human clinical trials with the potential of developing new cancer therapies.

Related Links:
University of Missouri



Channels

Radiography

view channel
Image: Agfa HealthCare’s DX-D Mobile Retrofit solution will allow hospitals an easy and affordable way to upgrade existing GE Healthcare’s AMX 4 and 4 plus mobile X-ray systems to direct radiography (DR) (Photo courtesy of Agfa Healthcare).

Retrofit Enables Cost-Effective Upgrade of Existing Mobile X-Ray Systems to Direct Radiography

A mobile retrofit system has been designed to be mounted on mobile X-ray systems to create an easy way for hospitals to go digital without having to replace existing mobile X-ray units. A direct radiography... Read more

MRI

view channel
Image: The ischemic penumbra is visible in some patients up to 24 hour after stroke by MRI scanning. Perfusion-weighted imaging can be used to show areas of ischemia and can be compared with the ischemic core, visible by diffusion-weighted imaging (Photo courtesy of sharinginginhealth dot ca, an open access training in healthcare resource).

Diffusion-Weighted MRI Becoming Major Tool to Diagnose Patients with Transient Ischemic Attacks

With the development of brain imaging, including cranial computed tomography (CCT), and particularly diffusion-weighted imaging-magnetic resonance imaging (DWI-MRI), the diagnosis of transient ischemic... Read more

Ultrasound

view channel
Image: Ultrasound image of the Circle of Willis (Photo courtesy of the Swedish Cerebrovascular Center, Seattle, WA, USA).

New Approaches for Transcanial Ultrasound Used for the Treatment of Brain Tumors and Targeted Drug Delivery

A study completed by a Finnish researcher provides new insights into the limitations and potential new directions for the future advancement of transcranial ultrasound therapy. Active research is ongoing... Read more

General/Advanced Imaging

view channel

Diagnostic Imaging Tests Ordered by General Practitioners in Australia Nearly Double in 10 Years

A 45% increase in diagnostic imaging tests ordered by Australian general practitioners (GPs) is being fueled by increasing GP visits, an escalating number of problems managed at doctor visits, and a higher probability that GPs order imaging tests for these problems, according to a new study. Based on a long-term national... Read more

Imaging IT

view channel
Image: An X-ray using the ClearRead bone suppression software technology (Photo courtesy of Riverain Technologies).

Bone Suppression Software Used to Optimize Diagnostic Capability of X-Ray Systems

Clinicians are gathering important information from the most routine imaging exam, the chest X-ray, by using advanced software that enhances X-ray images captured by the equipment they already have or... Read more

Industry News

view channel

Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.